Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients.

医学 塞维莱默 内科学 倾向得分匹配 人口 血液透析 磷酸盐粘合剂 透析 比例危险模型 外科 高磷血症 肾脏疾病 环境卫生
作者
Allan J. Collins,Wendy L. St. Peter,F Dalleska,James Ebben,J Z
出处
期刊:PubMed 卷期号:54 (4): 334-41 被引量:42
链接
标识
摘要

We evaluated 152 sevelamer hydrochloride treated Medicare patients on hemodialysis in a case-controlled study matching 152 randomly selected non-sevelamer hydrochloride treated Medicare patients from the same dialysis facilities and time period. The main outcomes evaluated were the risk of all-cause hospitalization and per-member per-month (PMPM) Medicare expenditures in the follow-up period.Medicare patients were identified from a total of 195 patients who were included in a long-term safety and efficacy clinical trial evaluating sevelamer hydrochloride [Chertow et al. 1999a]. The average serum calcium-phosphorus product as well as lipid profiles improved in the sevelamer hydrochloride treated group during the trial. Sevelamer treated patients were matched with randomly selected Medicare patients for age, gender, race, diabetic status, and geographic location. Comorbid conditions were characterized and sequential Cox regression models were applied with the outcome being risk of first hospitalization in a 17- month follow-up period.Across all four models, the relative risk of hospitalization was 46% to 54% less in the sevelamer hydrochloride treated group, as compared to the case control group (significant at the p-value 0.03 level). Overall, Medicare expenditures for the control patients per-member per-month were US-$4,745, compared to US-$3,368 in the sevelamer hydrochloride treated patients.Sevelamer hydrochloride treated patients had a 50% lower likelihood of hospitalization in the follow-up period after adjustments for the differences in the population. Potential bias may exist between groups because of differences in baseline characteristics that could not be adjusted for within the study design. We feel that to further advance this area, a randomized clinical trial should be performed.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
谜记完成签到,获得积分10
1秒前
共享精神应助Cheung2121采纳,获得30
1秒前
光撒盐完成签到,获得积分10
2秒前
cowboy007完成签到,获得积分10
2秒前
张振宇完成签到 ,获得积分10
3秒前
zz发布了新的文献求助10
4秒前
zzq778发布了新的文献求助10
6秒前
黄怡婷完成签到 ,获得积分10
6秒前
Daisy应助科研通管家采纳,获得10
7秒前
机智苗应助科研通管家采纳,获得10
7秒前
香蕉觅云应助科研通管家采纳,获得10
7秒前
FashionBoy应助科研通管家采纳,获得10
7秒前
赘婿应助科研通管家采纳,获得10
7秒前
大模型应助科研通管家采纳,获得10
7秒前
yanmu2010应助科研通管家采纳,获得10
7秒前
kingwill应助科研通管家采纳,获得20
8秒前
银包铜应助科研通管家采纳,获得10
8秒前
共享精神应助科研通管家采纳,获得10
8秒前
8秒前
情怀应助科研通管家采纳,获得10
8秒前
李爱国应助科研通管家采纳,获得10
8秒前
所所应助科研通管家采纳,获得10
8秒前
8秒前
Orange应助科研通管家采纳,获得10
8秒前
8秒前
8秒前
Lucas完成签到,获得积分10
10秒前
C胖胖完成签到,获得积分10
10秒前
舒心的完成签到,获得积分10
10秒前
zz完成签到,获得积分10
11秒前
12秒前
12秒前
12秒前
13秒前
luozejun完成签到,获得积分10
13秒前
ycp完成签到,获得积分10
14秒前
dawang完成签到 ,获得积分10
14秒前
洁净的智宸完成签到 ,获得积分10
14秒前
zhaopeipei发布了新的文献求助10
14秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029